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Abstract 
Forkhead box P3 (FOXP3), a gene member of the forkhead/winged-helix family of transcription regulators, is 
implicated in regulating immune system development and function. This gene has been found to be of crucial 
importance for the generation of CD4+CD25+ regulatory T cells (Tregs). In addition to its expression in the 
lymphocyte lineage, studies have recently described FOXP3 expression in normal and cancer cells non-
hematopoietic-derived, suggesting that FOXP3 exerts a broader function than that on Tregs. 
A role for FOXP3 as an onco-suppressor gene in human cancers has been suggested based on in vitro studies 
showing that FOXP3 is implicated in repressing various oncogenes and enhancing expression of tumor-
suppressor genes. However, numerous studies in samples from human cancer patients showed a positive 
correlation between FOXP3 expression and poor prognosis, especially with metastasis. 
Further investigations are required to clarify the significance of FOXP3 expression in tumor cells and to identify 
the mechanisms by which it affects prognosis. 
 
Introduction 
Forkhead box P3 (FOXP3) is a member of the 
forkhead/winged-helix family of transcription 
regulators. This gene is involved in immune system 
responses and in the development and function of 
regulatory T cells (Tregs) (Fontenot et al., 2005; 
Sakaguchi et al., 2008). The FOXP3 gene is located 
on the X chromosome at Xp11.23 and it is 
submitted to X chromosome inactivation (Wang et 
al., 2009). This gene is highly conserved across 
mammals (Ziegler, 2006) and contains 11 coding 
exons and 3 non-coding exons (Bennett and Ochs, 
2001). FOXP3 protein contains four potential 
functional domains; repressor, zinc finger, leucine 
zipper and forkhead. Humans express both full-
length protein and three splice variants (Allan et al., 
2005; Kaur et al., 2010; Smith et al., 2006). The 
full-lenght form consists of 431-amino acids with a  
 
 
molecular weight of 47 kDa. The isoform 
∆2FOXP3, lacking exon 2 (aa 71-105), has been 
proposed to act as a dominant negative isoform (Li 
et al., 2007). Another splice variant of FOXP3, 
called ∆7FOXP3, has been identified in both CD4+ 
and CD8+ regulatory T cell clones. ∆7FOXP3 lacks 
the 81 bp region that encodes exon 7. The absence 
of this exon abrogates the suppressive function of 
Tregs (Kaur et al., 2010). Human Tregs can also 
express ∆2∆7FOXP3 isoform that lacks both exon 
2 and exon 7 (aa 245-272) (Mailer et al., 2009). 
FOXP3 expression in regulatory T 
cells 
The nuclear expression of FOXP3 is considered as 
the most specific marker for Tregs and a key 
determinant of their immunosuppressive functions 
(Grimmig et al., 2013). The molecular mechanisms 
of Treg-mediated immunosuppression are still not  
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completely understood. Genome-wide analyses of 
FOXP3+ T cells revealed about 700 genes and 
many microRNAs differentially expressed in 
FOXP3+ Tregs. In these cells FOXP3 has a dual 
role as both transcriptional activator and repressor 
(Sadlon et al., 2010; Zheng et al., 2007). 
Regulatory T cells represent about 5% of 
circulating CD4+ T lymphocytes in the human 
peripheral blood. An increased number of Tregs has 
been observed in the blood, in the tumor mass and 
in the draining lymph nodes of patients with 
different solid tumors (Bergmann et al., 2008; 
Mougiakakos et al., 2010; Petersen et al., 2006; 
Strauss et al., 2007; Whiteside, 2012). The 
increased frequency of tumor-infiltrating Tregs 
have been associated with poor survival in breast 
(Bates et al., 2006), gastric (Sasada et al., 2003), 
ovarian (Sato et al., 2005), lung (Petersen et al., 
2006), hepatocellular (Gao et al., 2007), renal (Li et 
al., 2009), and pancreatic (Hiraoka et al., 2006) 
cancers. 
After migrating to tumor site, Tregs suppress 
antitumor immune response interfering with the 
activation and expansion of tumor-antigens-specific 
effector T cells through different mechanisms not 
fully understood yet (Whiteside, 2008). 
In breast cancer, the percentage of Treg cells 
increases in parallel with the disease stage, from 
normal to ductal carcinoma in situ (DCIS) and from 
DCIS to invasive carcinoma. A high frequency of 
tumor-infiltrating FOXP3+ cells correlates with 
worse disease-free survival and decreased overall 
survival in patients with invasive breast carcinoma, 
suggesting that the presence of Treg cells promotes 
tumour progression by creating an 
immunosuppressive environment (Bates et al., 
2006). 
Tan and colleagues proposed a further explanation 
for the association of Treg cells with an aggressive 
phenotype in advanced breast cancers by 
demonstrating that tumor-infiltrating FOXP3+ 
Tregs are responsible for high RANKL expression 
within the tumor microenvironment, and this 
expression stimulates the metastatic progression of 
RANK-expressing breast carcinoma cells (Tan et 
al., 2011). 
Tregs are also directly involved in promoting 
angiogenesis in the tumor microenvironment 
(Facciabene et al., 2012), therefore Tregs might 
promote cancer growth both through tumor immune 
escape and angiogenesis. 
In addition to their potential role in favoring disease 
progression and relapse, FOXP3+ Tregs have been 
suggested as possible biomarker to monitor the 
therapeutic response. For example, it has been 
observed that the decrease of FOXP3+ tumor-
infiltrating cells is associated with the pathological  
complete response in breast cancer patients  
 
submitted to neoadiuvant chemotherapy (Ladoire et 
al., 2008). 
Contrary to the putative pro-tumorigenic effect, the 
presence of Tregs has been associated with a good 
prognosis in colorectal and head and neck cancers 
(Badoual et al., 2006; Ladoire et al., 2011). 
Although Tregs can potentially promote cancer 
progression, they can also attenuate inflammation. 
Because chronic inflammation is one of the critical 
processes promoting carcinogenesis and tumor 
growth, Tregs are able to down-regulate the pro-
tumorigenic inflammatory responses. It has been 
hypothesized that colorectal cancer growth can be 
promoted by a Th17-cell mediated inflammatory 
response. Human Tregs are able to limit Th17-
related pro-tumorigenic effects through inhibition 
of their activation and function (Crome et al., 
2010). 
FOXP3 expression in malignant 
cells 
FOXP3 expression has been recently described in 
normal cells and in non-hematopoietic-derived 
cancer cells, suggesting that FOXP3 biological 
effects are not restricted to Tregs. FOXP3 
expression has been observed in different cancer 
histotypes (breast, urinary bladder, tongue, gastric, 
esophageal, pancreas, colorectal, stomach, thyroid, 
glioma, non-small cell lung cancers and 
melanoma). Studies performed on samples from 
human cancer patients have produced data showing 
FOXP3 expression restricted only to cancer cells, 
whereas weak or no FOXP3 expression was 
detectable in their respective normal counterpart 
(Ebert et al., 2008; Fu et al., 2013; Hinz et al., 
2007; Wang et al., 2012; Wang et al., 2014; Won et 
al., 2013). 
In contrast, Zuo and colleagues reported a higher 
expression of FOXP3 in normal epithelial breast 
cells than in tumor cells (Zuo et al., 2007b). Similar 
findings have been reported in samples of prostate 
and ovarian cancer, where FOXP3 protein was 
clearly identifiable in normal epithelial samples, 
while the majority of malignant cells resulted 
negative for this protein (Wang et al., 2009; Zhang 
and Sun, 2010). 
To note in most carcinomas, FOXP3 staining was 
localized predominantly in the cytoplasm of tumor 
cells, whereas in the studies by Zuo and Wang only 
nuclear positivity for FOXP3 was scored as a 
positive result (Wang et al., 2009; Zuo et al., 
2007b). 
Tumor suppressive role of 
FOXP3 
In vitro studies demonstrated an important role of 
FOXP3 modulating the expression of various genes  
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implicated in cancer development, including tumor 
suppressors and oncogenes. 
For instance, FOXP3 represses the expression of 
HER2 and SKP2 in breast cancer cells (Zuo et al., 
2007a; Zuo et al., 2007b) and an inverse correlation 
between FOXP3 and HER2 mRNA was observed 
in this type of tumor. Similarly, FOXP3 silencing in 
normal mammary epithelial cells (where FOXP3 is 
expressed at higher level compared to tumor tissue) 
determines an increase in HER2 expression (Zuo et 
al., 2007b). FOXP3 can also down-regulate 
BRCA1, interfering with the BRCA1-mediated 
DNA repair processes (Li et al., 2013). 
Moreover, FOXP3 is involved in the transcriptional 
control of tumor-suppressor genes such as p21 and 
LATS2 (Li et al., 2011). In prostate cancer, FOXP3 
is also able to repress the expression of c-Myc 
whose overexpression contributes to a more 
aggressive cancer phenotype (Wang et al., 2009). 
FOXP3 has been demonstrated to play a tumor-
suppressor role also in gastric cancer cells. In these 
cells the up-regulation of FOXP3 expression 
significantly inhibit cell growth and promote 
apoptosis, through the induction of pro-apoptotic 
genes (PARP, caspase-3 and caspase-9), suggesting 
that endogenous FOXP3 might act as a positive 
modulator in apoptotic pathway (Ma et al., 2013). 
Furthermore, in gastric cancer as in other 
malignancies, COX-2 has been shown to play an 
important role in both carcinogenesis and cancer 
progression. By inhibiting NF-κB activity, which is 
a major modulator of COX-2 expression, FOXP3 
inhibits the expression of COX2 and hence cell 
metastasis (Hao et al., 2014). 
FOXP3 expression and prognosis 
in human cancer 
Although FOXP3 has been described as an onco-
suppressor gene, recent evidences point out the 
positive correlation between FOXP3 expression and 
poor prognosis. 
In 2009, Merlo and colleagues demonstrated, for 
the first time, that FOXP3 expression in breast 
carcinoma was inversely associated with patient 
survival and that the risk increased with FOXP3 
staining intensity. FOXP3 was also a strong 
prognostic factor for distant metastasis-free 
survival, but not for local recurrence incidence risk 
(Merlo et al., 2009). These results were confirmed 
by other 2 independent studies (Kim MH et al., 
2013; Nair et al., 2013). 
The frequency of FOXP3 positive cancer cells in 
primary gastric tumors correlated with the 
incidence of lymph node metastases (Yoshii et al., 
2012; Wang et al., 2010) and the 3-year survival 
rate, indicating a potential association of FOXP3 
expression with poor prognosis. In this regard, it 
has been demonstrated that gastric carcinoma cells 
might have a Treg-like activity, which would allow 
them to escape from immune surveillance, thereby 
resulting in cancer progression (Yoshii et al., 2012). 
A correlation between FOXP3 expression and 
lymph node metastases incidence was also reported 
for esophageal squamous carcinoma (Xue et al., 
2010), where FOXP3 mRNA and protein 
expression was not only higher in tumors than in 
normal mucosa, but also higher in advanced stages 
than in early stages. FOXP3 negative patients 
experienced significantly better overall survival 
than the FOXP3-overexpressing group. Cox 
regression analysis showed that tumor stage and 
FOXP3 protein expression were independent 
prognostic risk factors (Wang et al., 2012). 
Two different studies on non-small-cell lung cancer 
patients demonstrated that FOXP3 expression in 
cancer cells positively correlated with both lymph 
node metastases and tumor staging 
(Dimitrakopoulos et al., 2011; Fu et al., 2013). 
FOXP3 expression has been correlated with poor 
prognosis even in colorectal (Kim M et al., 2013), 
tongue (Liang et al., 2011), urinary bladder 
(Winerdal et al., 2011) cancer patients, and glioma 
(Wang et al., 2014) patients. 
Finally, in vitro studies demonstrated that FOXP3 
expression in tumor cells correlates with the 
inhibition of T-cell proliferation, indicating that 
FOXP3-positive cancer cells may acquire growth-
suppressive functions, similar to Tregs, and that 
mimicking Tregs functions may represent a novel 
mechanism of immune evasion (Grimmig et al., 
2013; Hinz et al., 2007). 
All this data highlights the association between 
FOXP3 expression in tumor cells and poor patient 
prognosis. Notably, FOXP3 has not been associated 
with local recurrence but only with a possible role 
in driving metastatic spread. 
FOXP3 localization in cancer 
cells and patient prognosis 
FOXP3 protein is synthesized in the cytoplasm of 
cells and then actively transported to the nucleus. 
As a transcription factor, the nuclear localization is 
required for its transcriptional repression function 
(Lopes et al., 2006). 
FOXP3 is expressed constitutively within the 
nucleus of Tregs and of those normal FOXP3-
expressing epithelial cells (Sakaguchi, 2005). By 
contrast, several studies demonstrated that FOXP3 
cytoplasmic staining was more aboundant, 
compared to nuclear expression, in several types of 
cancer (Hinz et al., 2007; Karanikas et al., 2008; 
Ladoire et al., 2011; Merlo et al., 2009; Tao et al., 
2012; Winerdal et al., 2011). 
The fact that many tumors display cytoplasmic 
staining may be a result of defects in the nuclear 
localization signals of FOXP3, possibly due to 
acquired mutations. Frequent FOXP3 gene 
mutations and deletions, together with post- 
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translational modifications and splicing variations 
may result in cytoplasmic localization of FOXP3 
protein in cancer cells (Wang et al., 2009; Hancock 
and Ozkaynak, 2009). Since the role of FOXP3 is 
transcription regulation, a cytoplasmic FOXP3 
localization could affect its biological role. The 
concept that FOXP3 cytoplasmic localization 
interferes with its onco-suppressive functions has 
been suggested by a recent study (Takenaka et al., 
2013). Nuclear FOXP3 expression has been 
associated significantly with an improved overall 
survival in breast cancer patients, whereas 
cytoplasmic FOXP3 expression in tumor cells was 
significantly associated with poor clinical outcome 
(Takenaka et al., 2013). A predominant cytoplasmic 
FOXP3 localization has also been described in 
melanoma and colorectal cancer, where FOXP3 
expression correlated with poor prognosis (Kim et 
al., 2013; Quaglino et al., 2011). 
In contrast with these findings cytoplasmic FOXP3 
expression was associated with better overall 
survival and disease-free survival in primary 
invasive HER2-overexpressing breast cancer 
patients (Ladoire et al., 2011). 
Conclusions 
Since Treg cells are significant mediators of tumor 
progression, targeting Tregs is under active 
investigation. Many studies have already 
demonstrated that Tregs depletion is a promising 
way to promote antitumor immunity and tumor 
regression (Jarry et al., 2014; Keenan et al., 2014; 
Reginato et al., 2013; Zhou et al., 2013). 
In contrast, despite the increasing knowledge about 
the biology of FOXP3, the prognostic value of its 
expression in human cancer cells remains still 
controversial. The mechanism by which FOXP3 
expression in tumor cells affects prognosis has not 
been fully elucidated yet. However, immune 
evasion, via FOXP3 expression in tumor cells, may 
represent the main strategy for cancer progression. 
Further investigations are needed to clarify the 
significance of FOXP3 expression, its regulatory 
mechanism and its association with prognosis of 
human cancer. Moreover, additional studies should 
be carried out to clarify whether FOXP3 sub-
cellular localization in tumor cells could be 
functionally relevant to the clinical prognosis. 
References 
Bennett CL, Ochs HD. IPEX is a unique X-linked syndrome 
characterized by immune dysfunction, polyendocrinopathy, 
enteropathy, and a variety of autoimmune phenomena. 
Curr Opin Pediatr. 2001 Dec;13(6):533-8 
Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A. 
CD4+CD25+ regulatory T cells in patients with 
gastrointestinal malignancies: possible involvement of 
regulatory T cells in disease progression. Cancer. 2003 
Sep 1;98(5):1089-99 
 
Allan SE, Passerini L, Bacchetta R, Crellin N, Dai M, 
Orban PC, Ziegler SF, Roncarolo MG, Levings MK. The 
role of 2 FOXP3 isoforms in the generation of human 
CD4+ Tregs. J Clin Invest. 2005 Nov;115(11):3276-84 
Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A 
function for interleukin 2 in Foxp3-expressing regulatory T 
cells. Nat Immunol. 2005 Nov;6(11):1142-51 
Sakaguchi S. Naturally arising Foxp3-expressing 
CD25+CD4+ regulatory T cells in immunological tolerance 
to self and non-self. Nat Immunol. 2005 Apr;6(4):345-52 
Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, 
Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner 
J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, 
Odunsi K. Intraepithelial CD8+ tumor-infiltrating 
lymphocytes and a high CD8+/regulatory T cell ratio are 
associated with favorable prognosis in ovarian cancer. 
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43 
Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, 
Agueznay Nel H, Mosseri V, Laccourreye O, Bruneval P, 
Fridman WH, Brasnu DF, Tartour E. Prognostic value of 
tumor-infiltrating CD4+ T-cell subpopulations in head and 
neck cancers. Clin Cancer Res. 2006 Jan 15;12(2):465-72 
Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, 
Banham AH. Quantification of regulatory T cells enables 
the identification of high-risk breast cancer patients and 
those at risk of late relapse. J Clin Oncol. 2006 Dec 
1;24(34):5373-80 
Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence 
of FOXP3+ regulatory T cells increases during the 
progression of pancreatic ductal adenocarcinoma and its 
premalignant lesions. Clin Cancer Res. 2006 Sep 
15;12(18):5423-34 
Lopes JE, Torgerson TR, Schubert LA, Anover SD, 
Ocheltree EL, Ochs HD, Ziegler SF. Analysis of FOXP3 
reveals multiple domains required for its function as a 
transcriptional repressor. J Immunol. 2006 Sep 
1;177(5):3133-42 
Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi 
MB, Harpole DH Jr, Patz EF Jr. Tumor infiltrating Foxp3+ 
regulatory T-cells are associated with recurrence in 
pathologic stage I NSCLC patients. Cancer. 2006 Dec 
15;107(12):2866-72 
Smith EL, Finney HM, Nesbitt AM, Ramsdell F, Robinson 
MK. Splice variants of human FOXP3 are functional 
inhibitors of human CD4+ T-cell activation. Immunology. 
2006 Oct;119(2):203-11 
Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol. 
2006;24:209-26 
Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, 
Li YW, Tang ZY. Intratumoral balance of regulatory and 
cytotoxic T cells is associated with prognosis of 
hepatocellular carcinoma after resection. J Clin Oncol. 
2007 Jun 20;25(18):2586-93 
Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, 
Grüssel S, Sipos B, Grützmann R, Pilarsky C, Ungefroren 
H, Saeger HD, Klöppel G, Kabelitz D, Kalthoff H. Foxp3 
expression in pancreatic carcinoma cells as a novel 
mechanism of immune evasion in cancer. Cancer Res. 
2007 Sep 1;67(17):8344-50 
Li B, Samanta A, Song X, Iacono KT, Bembas K, Tao R, 
Basu S, Riley JL, Hancock WW, Shen Y, Saouaf SJ, 
Greene MI. FOXP3 interactions with histone 
acetyltransferase and class II histone deacetylases are 
required for repression. Proc Natl Acad Sci U S A. 2007 
Mar 13;104(11):4571-6 
FOXP3 expression in tumor cells and its role in cancer 
progression 





Atlas Genet Cytogenet Oncol Haematol. 2015; 19(3) 238 
Strauss L, Bergmann C, Gooding W, Johnson JT, 
Whiteside TL. The frequency and suppressor function of 
CD4+CD25highFoxp3+ T cells in the circulation of patients 
with squamous cell carcinoma of the head and neck. Clin 
Cancer Res. 2007 Nov 1;13(21):6301-11 
Zheng Y, Josefowicz SZ, Kas A, Chu TT, Gavin MA, 
Rudensky AY. Genome-wide analysis of Foxp3 target 
genes in developing and mature regulatory T cells. Nature. 
2007 Feb 22;445(7130):936-40 
Zuo T, Liu R, Zhang H, Chang X, Liu Y, Wang L, Zheng P, 
Liu Y. FOXP3 is a novel transcriptional repressor for the 
breast cancer oncogene SKP2. J Clin Invest. 2007a 
Dec;117(12):3765-73 
Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W, Liu 
Y, Wang Y, Liu X, Chan MW, Liu JQ, Love R, Liu CG, 
Godfrey V, Shen R, Huang TH, Yang T, Park BK, Wang 
CY, Zheng P, Liu Y. FOXP3 is an X-linked breast cancer 
suppressor gene and an important repressor of the HER-
2/ErbB2 oncogene. Cell. 2007b Jun 29;129(7):1275-86 
Bergmann C, Strauss L, Wang Y, Szczepanski MJ, Lang 
S, Johnson JT, Whiteside TL. T regulatory type 1 cells in 
squamous cell carcinoma of the head and neck: 
mechanisms of suppression and expansion in advanced 
disease. Clin Cancer Res. 2008 Jun 15;14(12):3706-15 
Ebert LM, Tan BS, Browning J, Svobodova S, Russell SE, 
Kirkpatrick N, Gedye C, Moss D, Ng SP, MacGregor D, 
Davis ID, Cebon J, Chen W. The regulatory T cell-
associated transcription factor FoxP3 is expressed by 
tumor cells. Cancer Res. 2008 Apr 15;68(8):3001-9 
Karanikas V, Speletas M, Zamanakou M, Kalala F, Loules 
G, Kerenidi T, Barda AK, Gourgoulianis KI, Germenis AE. 
Foxp3 expression in human cancer cells. J Transl Med. 
2008 Apr 22;6:19 
Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, 
Chauffert B, Fumoleau P, Ghiringhelli F. Pathologic 
complete response to neoadjuvant chemotherapy of breast 
carcinoma is associated with the disappearance of tumor-
infiltrating foxp3+ regulatory T cells. Clin Cancer Res. 2008 
Apr 15;14(8):2413-20 
Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory 
T cells and immune tolerance. Cell. 2008 May 
30;133(5):775-87 
Whiteside TL. The tumor microenvironment and its role in 
promoting tumor growth. Oncogene. 2008 Oct 
6;27(45):5904-12 
Hancock WW, Ozkaynak E. Three distinct domains 
contribute to nuclear transport of murine Foxp3. PLoS 
One. 2009 Nov 18;4(11):e7890 
Li JF, Chu YW, Wang GM, Zhu TY, Rong RM, Hou J, Xu 
M. The prognostic value of peritumoral regulatory T cells 
and its correlation with intratumoral cyclooxygenase-2 
expression in clear cell renal cell carcinoma. BJU Int. 2009 
Feb;103(3):399-405 
Mailer RK, Falk K, Rötzschke O. Absence of leucine zipper 
in the natural FOXP3Delta2Delta7 isoform does not affect 
dimerization but abrogates suppressive capacity. PLoS 
One. 2009 Jul 1;4(7):e6104 
Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi 
T, Mènard S, Tagliabue E, Balsari A. FOXP3 expression 
and overall survival in breast cancer. J Clin Oncol. 2009 
Apr 10;27(11):1746-52 
Wang L, Liu R, Li W, Chen C, Katoh H, Chen GY, McNally 
B, Lin L, Zhou P, Zuo T, Cooney KA, Liu Y, Zheng P.  
Somatic single hits inactivate the X-linked tumor 
suppressor FOXP3 in the prostate. Cancer Cell. 2009 Oct 
6;16(4):336-46 
Crome SQ, Clive B, Wang AY, Kang CY, Chow V, Yu J, 
Lai A, Ghahary A, Broady R, Levings MK. Inflammatory 
effects of ex vivo human Th17 cells are suppressed by 
regulatory T cells. J Immunol. 2010 Sep 15;185(6):3199-
208 
Kaur G, Goodall JC, Jarvis LB, Hill Gaston JS. 
Characterisation of Foxp3 splice variants in human CD4+  
and CD8+ T cells--identification of Foxp3∆7 in human 
regulatory T cells. Mol Immunol. 2010 Nov-Dec;48(1-
3):321-32 
Mougiakakos D, Choudhury A, Lladser A, Kiessling R, 
Johansson CC. Regulatory T cells in cancer. Adv Cancer 
Res. 2010;107:57-117 
Sadlon TJ, Wilkinson BG, Pederson S, Brown CY, Bresatz 
S, Gargett T, Melville EL, Peng K, D'Andrea RJ, Glonek 
GG, Goodall GJ, Zola H, Shannon MF, Barry SC. 
Genome-wide identification of human FOXP3 target genes 
in natural regulatory T cells. J Immunol. 2010 Jul 
15;185(2):1071-81 
Wang LH, Su L, Wang JT. Correlation between elevated 
FOXP3 expression and increased lymph node metastasis 
of gastric cancer. Chin Med J (Engl). 2010 
Dec;123(24):3545-9 
Xue L, Lu HQ, He J, Zhao XW, Zhong L, Zhang ZZ, Xu ZF. 
Expression of FOXP3 in esophageal squamous cell 
carcinoma relating to the clinical data. Dis Esophagus. 
2010 May;23(4):340-6 
Zhang HY, Sun H. Up-regulation of Foxp3 inhibits cell 
proliferation, migration and invasion in epithelial ovarian 
cancer. Cancer Lett. 2010 Jan 1;287(1):91-7 
Dimitrakopoulos FI, Papadaki H, Antonacopoulou AG, 
Kottorou A, Gotsis AD, Scopa C, Kalofonos HP, Mouzaki 
A. Association of FOXP3 expression with non-small cell 
lung cancer. Anticancer Res. 2011 May;31(5):1677-83 
Ladoire S, Martin F, Ghiringhelli F. Prognostic role of 
FOXP3+ regulatory T cells infiltrating human carcinomas: 
the paradox of colorectal cancer. Cancer Immunol 
Immunother. 2011 Jul;60(7):909-18 
Li W, Wang L, Katoh H, Liu R, Zheng P, Liu Y. 
Identification of a tumor suppressor relay between the 
FOXP3 and the Hippo pathways in breast and prostate 
cancers. Cancer Res. 2011 Mar 15;71(6):2162-71 
Liang YJ, Liu HC, Su YX, Zhang TH, Chu M, Liang LZ, 
Liao GQ. Foxp3 expressed by tongue squamous cell 
carcinoma cells correlates with clinicopathologic features 
and overall survival in tongue squamous cell carcinoma 
patients. Oral Oncol. 2011 Jul;47(7):566-70 
Quaglino P, Osella-Abate S, Marenco F, Nardò T, Gado C, 
Novelli M, Savoia P, Bernengo MG. FoxP3 expression on 
melanoma cells is related to early visceral spreading in 
melanoma patients treated by electrochemotherapy. 
Pigment Cell Melanoma Res. 2011 Aug;24(4):734-6 
Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, 
Hoffman RM, Karin M. Tumour-infiltrating regulatory T cells 
stimulate mammary cancer metastasis through RANKL-
RANK signalling. Nature. 2011 Feb 24;470(7335):548-53 
Winerdal ME, Marits P, Winerdal M, Hasan M, Rosenblatt 
R, Tolf A, Selling K, Sherif A, Winqvist O. FOXP3 and 
survival in urinary bladder cancer. BJU Int. 2011 
Nov;108(10):1672-8 
FOXP3 expression in tumor cells and its role in cancer 
progression 





Atlas Genet Cytogenet Oncol Haematol. 2015; 19(3) 239 
Facciabene A, Motz GT, Coukos G. T-regulatory cells: key 
players in tumor immune escape and angiogenesis. 
Cancer Res. 2012 May 1;72(9):2162-71 
Tao H, Mimura Y, Aoe K, Kobayashi S, Yamamoto H, 
Matsuda E, Okabe K, Matsumoto T, Sugi K, Ueoka H. 
Prognostic potential of FOXP3 expression in non-small cell  
lung cancer cells combined with tumor-infiltrating 
regulatory T cells. Lung Cancer. 2012 Jan;75(1):95-101 
Wang G, Liu G, Liu Y, Li X, Su Z. FOXP3 expression in 
esophageal cancer cells is associated with poor prognosis 
in esophageal cancer. Hepatogastroenterology. 2012 
Oct;59(119):2186-91 
Whiteside TL. What are regulatory T cells (Treg) regulating 
in cancer and why? Semin Cancer Biol. 2012 
Aug;22(4):327-34 
Yoshii M, Tanaka H, Ohira M, Muguruma K, Iwauchi T, 
Lee T, Sakurai K, Kubo N, Yashiro M, Sawada T, 
Hirakawa K. Expression of Forkhead box P3 in tumour 
cells causes immunoregulatory function of signet ring cell 
carcinoma of the stomach. Br J Cancer. 2012 May 
8;106(10):1668-74 
Fu HY, Li C, Yang W, Gai XD, Jia T, Lei YM, Li Y. FOXP3 
and TLR4 protein expression are correlated in non-small 
cell lung cancer: implications for tumor progression and 
escape. Acta Histochem. 2013 Mar;115(2):151-7 
Grimmig T, Kim M, Germer CT, Gasser M, Waaga-Gasser 
AM. The role of FOXP3 in disease progression in 
colorectal cancer patients. Oncoimmunology. 2013 Jun 
1;2(6):e24521 
Kim M, Grimmig T, Grimm M, Lazariotou M, Meier E, 
Rosenwald A, Tsaur I, Blaheta R, Heemann U, Germer 
CT, Waaga-Gasser AM, Gasser M. Expression of Foxp3 in 
colorectal cancer but not in Treg cells correlates with 
disease progression in patients with colorectal cancer. 
PLoS One. 2013;8(1):e53630 
Kim MH, Koo JS, Lee S. FOXP3 expression is related to 
high Ki-67 index and poor prognosis in lymph node-
positive breast cancer patients. Oncology. 2013;85(2):128-
36 
Li W, Katoh H, Wang L, Yu X, Du Z, Yan X, Zheng P, Liu 
Y. FOXP3 regulates sensitivity of cancer cells to irradiation 
by transcriptional repression of BRCA1. Cancer Res. 2013 
Apr 1;73(7):2170-80 
Ma GF, Chen SY, Sun ZR, Miao Q, Liu YM, Zeng XQ, Luo 
TC, Ma LL, Lian JJ, Song DL. FoxP3 inhibits proliferation 
and induces apoptosis of gastric cancer cells by activating 
the apoptotic signaling pathway. Biochem Biophys Res 
Commun. 2013 Jan 11;430(2):804-9 
Nair S, Aldrich AJ, McDonnell E, Cheng Q, Aggarwal A,  
Patel P, Williams MM, Boczkowski D, Lyerly HK, Morse 
MA, Devi GR. Immunologic targeting of FOXP3 in 
inflammatory breast cancer cells. PLoS One. 
2013;8(1):e53150 
Reginato E, Mroz P, Chung H, Kawakubo M, Wolf P, 
Hamblin MR. Photodynamic therapy plus regulatory T-
celldepletion produces immunity against a mouse tumour 
that expresses a self-antigen. Br J Cancer. 2013 Oct 
15;109(8):2167-74 
Takenaka M, Seki N, Toh U, Hattori S, Kawahara A, 
Yamaguchi T, Koura K, Takahashi R, Otsuka H, Takahashi 
H, Iwakuma N, Nakagawa S, Fujii T, Sasada T, 
Yamaguchi R, Yano H, Shirouzu K, Kage M. FOXP3 
expression in tumor cells and tumor-infiltrating 
lymphocytes is associated with breast cancer prognosis. 
Mol Clin Oncol. 2013 Jul;1(4):625-632 
Won KY, Kim HS, Sung JY, Kim GY, Lee J, Park YK, Kim 
YW, Suh JH, Lim SJ. Tumoral FOXP3 has potential 
oncogenic function in conjunction with the p53 tumor 
suppressor protein and infiltrated Tregs in human breast 
carcinomas. Pathol Res Pract. 2013 Dec;209(12):767-73 
Zhou S, Chen L, Qin J, Li R, Tao H, Zhen Z, Chen H, Chen 
G, Yang Y, Liu B, She Z, Zhong C, Liang C. Depletion of 
CD4+ CD25+ regulatory T cells promotes CCL21-
mediated antitumor immunity. PLoS One. 
2013;8(9):e73952 
Hao Q, Zhang C, Gao Y, Wang S, Li J, Li M, Xue X, Li W, 
Zhang W, Zhang Y. FOXP3 inhibits NF-κB activity and 
hence COX2 expression in gastric cancer cells. Cell 
Signal. 2014 Mar;26(3):564-9 
Jarry U, Donnou S, Vincent M, Jeannin P, Pineau L, 
Fremaux I, Delneste Y, Couez D. Treg depletion followed 
by intracerebral CpG-ODN injection induce brain tumor 
rejection. J Neuroimmunol. 2014 Feb 15;267(1-2):35-42 
Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, 
Maitra A, Rucki AA, Gunderson AJ, Coussens LM, 
Brockstedt DG, Dubensky TW Jr, Hassan R, Armstrong 
TD, Jaffee EM. A Listeria vaccine and depletion of T-
regulatory cells activate immunity against early stage 
pancreatic intraepithelial neoplasms and prolong survival 
of mice. Gastroenterology. 2014 Jun;146(7):1784-94.e6 
Wang L, Zhang B, Xu X, Zhang S, Yan X, Kong F, Feng X, 
Wang J. Clinical significance of FOXP3 expression in 
human gliomas. Clin Transl Oncol. 2014 Jan;16(1):36-43 
This article should be referenced as such: 
Uva V, Sfondrini L, Triulzi T, Casalini P, Tagliabue E, 
Balsari A. FOXP3 expression in tumor cells and its role in 
cancer progression. Atlas Genet Cytogenet Oncol 
Haematol. 2015; 19(3):234-239. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
